Quantifiable PSMA PET measure could simplify prostate cancer risk assessment

A quantitative measure of tumor burden on prostate-specific membrane antigen (PSMA) PET scans may provide a reliable way to predict overall survival in patients with prostate cancer, according to a new study involving nearly 14,000 patients. 

Experts say their findings suggest that the overall volume of PSMA-positive disease may offer more useful prognostic information than individual measures of tracer uptake or PSA testing alone. Unlike composite metrics requiring multiple measurements, total tumor volume—a measure of the volume of PSMA-positive disease throughout the body—provides a single quantifiable gauge of disease burden. 

“Recently, PSMA PET standardized by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) was identified as prognostic imaging biomarker, and PSMA PET PROMISE (PPP3) risk nomograms were created to predict ... overall survival,” Madeleine J. Karpinski, with the department of nuclear medicine at University Hospital Essen in Germany, and colleagues noted. “Despite the global availability of PPP3 nomograms in free web-based software, standardization of PSMA PET by PROMISE still requires expert reader input. This could limit scalability and integration of PROMISE into automated systems and workflows."

The study compared the prognostic performance of PSMA total tumor volume with other quantitative imaging and clinical biomarkers. Researchers analyzed data from patients with histologically confirmed prostate cancer who underwent PSMA PET between 2012 and 2024. Participants were divided into development and validation cohorts. 

Subscribe to Radiology Business News

In the validation cohort, PSMA total tumor volume demonstrated a C-index of 0.78 for predicting overall survival. This was higher than the performance of whole-body SUVmean (0.62) and PSA level at the time of PET imaging (0.71). Its accuracy was similar to PSMA total lesion uptake, which is calculated by multiplying total tumor volume by SUVmean (0.78), and PSA adjusted for tumor volume (0.77). 

Researchers also found a clear relationship between PSMA total tumor volume and survival. Patients in the lowest tumor volume quartiles had median overall survival that was not reached during follow-up. Median survival was 11.4 years among patients in the third quartile, with tumor volumes greater than 2.1 to 16.2 mL, and 4.4 years among those in the highest quartile, with volumes exceeding 16.2 mL. 

The study builds on previous work using PROMISE criteria to assess PSMA PET findings and predict outcomes. The investigators suggest that automated total tumor volume measurement could eventually make survival prediction faster and more reproducible across imaging centers. However, additional research is needed to establish how automated assessment can be incorporated into routine clinical practice and whether it can improve treatment planning. 

Read more here. 

Hannah Murphy
Hannah Murphy, Editor

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Subscribe to Radiology Business News

Subscribe to Radiology Business News